Explorer les evidences

50 %The mortality rate of cryptococcal meningitis was 50%.

Côte d'Ivoireméningite cryptococciqueobservé 2008 to 2011publié 2017Journal de mycologie medicaleeurope_pmcdocument de 11 observations

1,42 per_100_person_monthsDuring the pre-intervention period, the incidence rates were 1.42 cases per 100 person-months in the LLIN-alone control group.

Côte d'IvoirepaludismeHAL · Unilimdocument de 54 observations

1,07 adjusted_IRRHBsAg-positive individuals with HBV-DNA ≥2000 IU/mL had an adjusted incidence rate ratio for mortality of 1.07 (95% CI = 0.01–4.91) at CD4+ counts >500/mm³ compared to HBsAg-negative individuals.

Côte d'Ivoirehépatite B · VIH/sidapublié 2021Antiviral therapyeurope_pmcdocument de 4 observations

0,98 %The sporozoite infection prevalence was 0.98% in the LLIN-only group and 0.5% in the LLIN + BTI group.

Côte d'IvoirepaludismeHAL · Unilimdocument de 54 observations

2,7 %Among 879 participants in the Temprano randomized control trial, 24 (2.7%) had hepatitis B surface antigen (HBsAg)-positive with HBV DNA ≥ 2,000 IU/ml.

Côte d'Ivoirehépatite Bobservé 2008 and 2015publié 2021Journal of viral hepatitiseurope_pmcdocument de 5 observations

46 casesForty-six cases of cryptococcal meningitis were identified, representing 2.5% of hospitalizations.

Côte d'Ivoireméningite cryptococciqueobservé 2008 to 2011publié 2017Journal de mycologie medicaleeurope_pmcdocument de 11 observations

The prevalence of symptomatic malaria cases decreased significantly with age.

Côte d'IvoirepaludismeHAL · Unilimdocument de 122 observations

90,3 %28 (90.3%) of the HIV-2 patients were on PI-based ART-regimen at enrolment.

Côte d'IvoireVIH/sidapublié 2020PloS oneeurope_pmcdocument de 13 observationsDOI 10.1371/journal.pone.0236642

46 %The proportion of Pfcrt-76T mutant allele was 46% in Abobo, Ivory Coast.

Côte d'Ivoirepaludismeobservé 2009publié 2019Bulletin de la Societe de pathologie exotique (1990)europe_pmcdocument de 5 observations

0,57 sensitivityA ≥ 1.0 log10 IU/mL drop in qHBsAg at month 12 had sensitivity of 0.57 and specificity of 1.00 for predicting HBsAg seroclearance at month 36.

Côte d'Ivoirehépatite Bobservé month 36publié 2016Journal of gastroenterology and hepatologyeurope_pmcdocument de 11 observationsDOI 10.1111/jgh.13156

All three patients had received antiretroviral therapy for more than four years, including lopinavir/ritonavir for more than eight months.

Côte d'IvoireVIH/sidapublié 2009Antiviral therapyeurope_pmcdocument de 11 observations

82,1 %82.1% of HIV-infected female sex workers in Abidjan, Côte d'Ivoire were on antiretroviral therapy.

Côte d'IvoireVIH/sidaobservé 2013publié 2015BMC oral healtheurope_pmcdocument de 7 observations

245 patientsOf 245 patients followed for up to 3 years in a cohort of HIV-infected patients of sub-Saharan African origin, the incidence of metabolic syndrome, insulin resistance, and lipodystrophy was observed.

Côte d'IvoireVIH/sidapublié 2015AIDS research and human retroviruseseurope_pmcdocument de 7 observations

86,9 %Of 237 HIV-infected patients from two clinical trials, 206 (86.9%) tested positive for hepatitis B surface antigen (HBsAg) using MiniVidas® and had validated serological tests using Architect.

Côte d'Ivoirehépatite B · VIH/sidapublié 2015Diagnostic microbiology and infectious diseaseeurope_pmc

80 %The proportion of HIV-infected patients reaching CD4+ T cell counts >350/mm³ after six months of ART was 80.0% in the HBV coinfection with low HBV-DNA replication group.

Côte d'IvoireHIV-hepatitis B virus coinfectionpublié 2018AIDS research and human retroviruseseurope_pmcdocument de 4 observations

Among 791 HIV-infected patients in West Africa, HBsAg positivity was 7.9% in HIV-1 patients, 7.2% in HIV-1&2 dually reactive patients, and 9.4% in HIV-2 patients.

Côte d'Ivoirehépatite B · VIH/sidaobservé 2012publié 2017BMC infectious diseaseseurope_pmcdocument de 7 observations

9,5 per_100_person_yearsIn patients with pre-ART CD4 cell count 200–349 cells/μL, incidence of severe morbidity was 9.5 per 100 person-years.

Côte d'IvoireVIH/sidapublié 2007AIDS (London, England)europe_pmcdocument de 9 observations

159 per_100000In Côte d'Ivoire, the incidence of tuberculosis was 159 per 100,000 people.

Côte d'Ivoiretuberculosepublié 2017The Lancet. Global healtheurope_pmcdocument de 6 observations

2,1 %Salmonella enterica Paratyphi was detected in 2.1% of febrile people in Côte d'Ivoire.

Côte d'IvoireSalmonella enterica Paratyphipublié 2021Travel medicine and infectious diseasePubMeddocument de 25 observations

69 %Cotrimoxazole led to a 69% reduction in the risk of malaria.

Côte d'Ivoirepaludismepublié 2017Tropical medicine & international health : TM & IHeurope_pmcdocument de 4 observationsDOI 10.1111/tmi.12919

10 childrenThe study included 10 children and 89 adolescents victims of rape in Abidjan between 2000 and 2013.

Côte d'IvoireVIH/sidaobservé 2000-2013publié 2015Medecine et maladies infectieuseseurope_pmcdocument de 3 observations

12 %Among HIV-infected adults interviewed, 12% with more than 500 CD4+ cells/μl had a seronegative partner and should be recommended antiretroviral treatment (ART).

Côte d'IvoireVIH/sidapublié 2014AIDS (London, England)europe_pmcdocument de 5 observations

25,9 %The most frequently reported countries of contamination were Ivory Coast (25.9%), Democratic Republic of the Congo (24.1%) and Cameroon (13.2%).

Côte d'IvoirepaludismeHAL · Unilimdocument de 123 observations

0,8 rate_ratioIn Côte d'Ivoire, test positivity rates reported from DHIS2 declined significantly more in study than control facilities after study onset, with a rate ratio of 0.80 (95% CI 0.76, 0.84).

Côte d'Ivoirepaludismeobservé 2023publié 2025Malaria journalPubMeddocument de 5 observations

27 %For children living with HIV, AIDS-related illnesses accounted for 27% of hospital admissions.

Côte d'IvoireAIDS-related illnessespublié 2015The lancet. HIVeurope_pmcdocument de 8 observations